JP7385556B2 - Bcma抗原に特異的な免疫原性ペプチドおよびその使用 - Google Patents

Bcma抗原に特異的な免疫原性ペプチドおよびその使用 Download PDF

Info

Publication number
JP7385556B2
JP7385556B2 JP2020512512A JP2020512512A JP7385556B2 JP 7385556 B2 JP7385556 B2 JP 7385556B2 JP 2020512512 A JP2020512512 A JP 2020512512A JP 2020512512 A JP2020512512 A JP 2020512512A JP 7385556 B2 JP7385556 B2 JP 7385556B2
Authority
JP
Japan
Prior art keywords
peptide
cells
bcma
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532300A (ja
JP2020532300A5 (cg-RX-API-DMAC7.html
Inventor
ジョーウン ベ,
ニクヒル シー. ムンシ,
ケネス シー. アンダーソン,
Original Assignee
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド
Publication of JP2020532300A publication Critical patent/JP2020532300A/ja
Publication of JP2020532300A5 publication Critical patent/JP2020532300A5/ja
Priority to JP2023192306A priority Critical patent/JP7644200B2/ja
Application granted granted Critical
Publication of JP7385556B2 publication Critical patent/JP7385556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020512512A 2017-09-01 2018-08-31 Bcma抗原に特異的な免疫原性ペプチドおよびその使用 Active JP7385556B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192306A JP7644200B2 (ja) 2017-09-01 2023-11-10 Bcma抗原に特異的な免疫原性ペプチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553669P 2017-09-01 2017-09-01
US62/553,669 2017-09-01
PCT/US2018/049260 WO2019046818A1 (en) 2017-09-01 2018-08-31 SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192306A Division JP7644200B2 (ja) 2017-09-01 2023-11-10 Bcma抗原に特異的な免疫原性ペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2020532300A JP2020532300A (ja) 2020-11-12
JP2020532300A5 JP2020532300A5 (cg-RX-API-DMAC7.html) 2021-10-07
JP7385556B2 true JP7385556B2 (ja) 2023-11-22

Family

ID=63678690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512512A Active JP7385556B2 (ja) 2017-09-01 2018-08-31 Bcma抗原に特異的な免疫原性ペプチドおよびその使用
JP2023192306A Active JP7644200B2 (ja) 2017-09-01 2023-11-10 Bcma抗原に特異的な免疫原性ペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192306A Active JP7644200B2 (ja) 2017-09-01 2023-11-10 Bcma抗原に特異的な免疫原性ペプチドおよびその使用

Country Status (8)

Country Link
US (2) US11517591B2 (cg-RX-API-DMAC7.html)
EP (1) EP3675897A1 (cg-RX-API-DMAC7.html)
JP (2) JP7385556B2 (cg-RX-API-DMAC7.html)
KR (1) KR102794702B1 (cg-RX-API-DMAC7.html)
CN (1) CN111655280B (cg-RX-API-DMAC7.html)
AU (2) AU2018326805B2 (cg-RX-API-DMAC7.html)
CA (1) CA3070468A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019046818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12215349B2 (en) * 2016-12-13 2025-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511419A (ja) 1999-10-13 2003-03-25 トーステン アーラート ウイルス/抗原処理された樹状細胞による抗原特異的t細胞の活性化
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
EP0910409A4 (en) 1996-03-05 2003-03-19 Scripps Research Inst RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
EP1124568B1 (en) 1998-10-21 2007-08-22 Altor BioScience Corporation Polyspecific binding molecules and uses thereof
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
GB9930359D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
CN1312289A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人促性腺释放激素23和编码这种多肽的多核苷酸
NZ521629A (en) 2000-04-27 2004-05-28 Biogen Inc TACI as an anti-tumor agent
AU2001263114A1 (en) * 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1359937A4 (en) 2001-02-14 2004-07-28 Genzyme Corp MODIFIED PEPTIDE LIGANDS
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
KR20040019105A (ko) 2001-08-03 2004-03-04 제넨테크, 인크. TACIs 및 BR3 폴리펩티드 및 이의 용도
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20040072246A1 (en) 2001-09-11 2004-04-15 Roland Martin System and method for identifying t cell and other epitopes and the like
WO2005037995A2 (en) 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
EP1676132B1 (en) 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
WO2008143679A2 (en) * 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
ES2835200T3 (es) 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
JP6374392B2 (ja) * 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
PT2951202T (pt) 2013-01-29 2020-07-07 Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch Moléculas de ligação de alta avidez que reconhecem mage-a1
EP2968510B1 (en) 2013-03-14 2019-10-09 President and Fellows of Harvard College Nanoparticle-based compositions
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
EP3131927B8 (en) * 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3218404B1 (en) 2014-11-14 2021-01-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Human anti-thyroglobulin t cell receptors
BR112017014219A2 (en) 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
AU2016273213B2 (en) 2015-06-01 2019-03-14 Medigene Immunotherapies Gmbh T cell receptor library
US10228101B2 (en) 2015-07-01 2019-03-12 Mind Head Llc LED light fixtures and LED lamps that are used to replace Par 36 halogen lamps and incandescent well lights
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
NZ746700A (en) 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
PL3896091T3 (pl) * 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511419A (ja) 1999-10-13 2003-03-25 トーステン アーラート ウイルス/抗原処理された樹状細胞による抗原特異的t細胞の活性化
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Accession No. AB052772,Database GenBank [online],2002年,インターネット<https://www.ncbi.nlm.nih.gov/nuccore/AB052772.1>[検索日2022年7月13日]

Also Published As

Publication number Publication date
KR102794702B1 (ko) 2025-04-11
CN111655280A (zh) 2020-09-11
JP2020532300A (ja) 2020-11-12
CN111655280B (zh) 2025-01-14
AU2018326805A1 (en) 2020-02-13
AU2024200560B2 (en) 2025-06-05
WO2019046818A1 (en) 2019-03-07
AU2018326805B2 (en) 2023-11-30
US20230248769A1 (en) 2023-08-10
JP7644200B2 (ja) 2025-03-11
EP3675897A1 (en) 2020-07-08
CA3070468A1 (en) 2019-03-07
US20200352995A1 (en) 2020-11-12
AU2024200560A1 (en) 2024-02-29
US11517591B2 (en) 2022-12-06
JP2023184757A (ja) 2023-12-28
WO2019046818A9 (en) 2020-05-14
KR20200047660A (ko) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7644200B2 (ja) Bcma抗原に特異的な免疫原性ペプチドおよびその使用
US12448429B2 (en) T cell receptors specific to b-cell maturation antigen for treatment of cancer
JP7420856B2 (ja) T細胞を製造する組成物及び方法
JP2021521776A (ja) Mage−b2特異性を有するt細胞受容体およびその使用
AU2018203355A1 (en) Target peptides for immunotherapy and diagnostics
US11834516B2 (en) Tumor-specific polypeptide and use thereof
US20240285740A1 (en) Compositions and methods for treating cancer
JP7026970B2 (ja) 白血病およびその他のがんに対する免疫療法において使用するためのペプチドおよびペプチドの組み合わせ
US20220313803A1 (en) Novel neoantigens and cancer immunotherapy using same
TWI624475B (zh) 對於th1細胞之cdca1抗原決定位胜肽及含此之疫苗
US20200254078A1 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
AU2016306304A1 (en) Identification of class I MHC associated glycopertides as targets for cancer immunotherapy
US20260021184A1 (en) Cancer Antigens and Methods
WO2025224446A1 (en) Novel cancer antigens and methods
CN115151274B (zh) Hla限制性hormad1 t细胞受体及其用途
US20260102470A1 (en) Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
Jeon Role of toll-like receptor agonists as cancer vaccine adjuvants
RU2793344C2 (ru) Композиции и способы для производства т-клеток

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231110

R150 Certificate of patent or registration of utility model

Ref document number: 7385556

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150